.svg.png){kind=small}
.svg){kind=small}
Redefining Kidney Disease Through Strategic Collaborations
XORTX is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for acute kidney and other acute organ injury associated with Coronavirus / COVID-19 infection as well as XRx-225 which is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, they are dedicated to developing medications to improve the quality of life and future health of patients.
For more information on XORTX Therapeutics Inc. (TSX.V: XRTX) please click the request investor info button.
.png){kind=small}
